

Investor Contacts:

Arthur Shannon
arthur.shannon@bausch.com

Allison Ryan
allison.ryan@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735

Media Contacts:

Lainie Keller
lainie.keller@bausch.com
(908) 927-1198

Kristy Marks
kristy.marks@bausch.com
(908) 927-0683

Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congress

One Podium and Two Poster Presentations Will Highlight Pre-Clinical and Clinical Data for Investigational Treatment NOV03, as well as Data from Company's Unique ARMOR Surveillance Study

VAUGHAN, Ontario, Sept. 27, 2022 – Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of one podium and two poster presentations at the World Cornea Congress VIII meeting, which will take place in Chicago from Sept. 28-29, 2022.

The podium presentation will feature findings from the pivotal Phase 3 trials of the investigational treatment NOV03 (perfluorohexyloctane), and the poster presentations will include pre-clinical data of NOV03 and data from Bausch + Lomb’s ongoing Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study. The ARMOR study is the only ongoing surveillance study of its kind that evaluates profiles and trends in antibiotic resistance among common ocular bacterial pathogens across the United States.

“With the recent FDA acceptance of the New Drug Application for NOV03, we look forward to attending the World Cornea Congress so we can share valuable insights from our NOV03 clinical development program with the ophthalmic community,” said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb. “We will also present findings from our unique ARMOR study, which for more than a decade has helped guide eye care professionals in selecting the most appropriate antibiotic treatment options to meet the needs of their patients.”

Following is a complete list of titles and lead authors for each of the presentations:

Podium Presentation

- *“NOV03 for the Treatment of Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction: GOBI and MOJAVE Study Findings.”* Tauber et al.

Poster Presentations

- *“In Vitro Antibiotic Resistance among Bacterial Pathogens Sourced from the Cornea in ARMOR.”* Asbell et al.
- *“In Vitro Studies of Perfluorohexyloctane, an Investigational Eye Drop for Dry Eye Disease.”* Borchman et al.

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on [Twitter](#), [LinkedIn](#), [Facebook](#) and [Instagram](#).

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch + Lomb, including but not limited to its project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

###

*All product/brand names are trademarks of the respective owners.
© 2022 Bausch & Lomb Incorporated or its affiliates.
NOV03.0030.USA.22*